The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
|Articles|January 4, 2022
Daily Medication Pearl: Rivaroxaban (Xarelto)
Author(s)Saro Arakelians, PharmD
Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism.
Advertisement
Medication Pearl of the Day: Rivaroxaban (Xarelto)
Indication: Rivaroxaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and of PE, and for the prophylaxis of DVT that may lead to PE in patients undergoing knee or hip replacement surgery.
Insight:
- Dosing: Take 15 mg and 20 mg tablets with food. Take 10 mg tablets with or without food.
- Dosage forms: Tablets 10 mg, 15 mg, and 20 mg.
- Adverse events: The most common adverse reaction (>5%) was bleeding.
- Mechanism of action: Rivaroxaban is a selective inhibitor of FXa. It does not require a cofactor (such as anti-thrombin III) for activity.
- Manufacturer: Janssen Pharma
Sources:
Advertisement
Related to this article
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
4
Finerenone Receives FDA Approval for Treatment of Adults With CKD Associated With T1D
5